Blueprint Medicines Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Blueprint Medicines Stock Summary

Blueprint Medicines competes with Terns Pharmaceuticals, Amylyx Pharmaceuticals, Acumen Pharmaceuticals, Inozyme Pharma, and X4 Pharmaceuticals. Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 580 people.

Blueprint Medicines Key Financial Ratios

Blueprint Medicines Key Balance Sheet Accounts

Blueprint Medicines Key Income Statement Accounts

Blueprint Medicines Key Cash Accounts

Blueprint Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Blueprint Medicines's current stock value. Our valuation model uses many indicators to compare Blueprint Medicines value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Blueprint Medicines competition to find correlations between indicators driving Blueprint Medicines's intrinsic value. More Info.Blueprint Medicines Corp is rated fifth in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At present, Blueprint Medicines' Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Blueprint Medicines' earnings, one of the primary drivers of an investment's value.

Blueprint Medicines' Earnings Breakdown by Geography

Blueprint Medicines Corp Systematic Risk

Today, most investors in Blueprint Medicines Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Blueprint Medicines' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Blueprint Medicines growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Blueprint Medicines help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Blueprint Medicines Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Blueprint Medicines Corp based on widely used predictive technical indicators. In general, we focus on analyzing Blueprint Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Blueprint Medicines's daily price indicators and compare them against related drivers.

When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.